To apply up to date information about the natural history of menopause to improve the care of individual women
• To counsel women about the risks and benefits of systemic hormone therapy for menopausal symptoms, based on their personal risk profile
• To advise women about the relative efficacy, risks, and benefits of commonly used alternatives to systemic hormone therapy for treatment of menopausal symptoms, including: 
Case Presentation
A.R. is a 52 year old woman who presents with complaints of hot flashes, irritability, and diffuse muscle aches after stopping her HT when she heard it causes strokes.
However, a friend who lives in San Diego gave her a copy of a "Harvard Women's Health Watch" that suggests that since she has a high risk of heart disease, she should take HT. The same friend gave her a local newspaper article quoting famous gynecologists who said the same thing. She asks for your advice.
• When you return to the room after examining her, she presents you with a list of additional questions, including:
• I am having trouble with my memory, is it from my menopause?
• My friend has depression, is it because she is in menopause?
• Does estrogen cause breast cancer?
• If I take estrogen, is bioidentical safer?
• • "Menopausal HT should not be used for the primary or secondary prevention of CHD at the present time."
• "Recent evidence suggests that women in early menopause who are in good cardiovascular health are at low risk of adverse cardiac outcomes and should be considered candidates (for HT) for relief of menopausal symptoms."
• U.S. Preventative Services Task Force (USPSTF)
• The USPSTF recommends against the use of combined estrogen and progestin for the prevention of chronic conditions in postmenopausal women (Grade D: Evidence of Harm)
• The USPSTF recommends against the use of estrogen for the prevention of chronic conditions in postmenopausal women who have had a hysterectomy (Grade D: Evidence of Harm)
Principles of Hormone Treatment
• Guidelines recommend the "lowest effective dose", although different doses have not been comparatively studied, this seems a prudent approach
• Very important to add progestin in women with a uterus American College of Obstetricians and Gynecologists Committee Opinion August 2012 "Not only is evidence lacking to support superiority claims of compounded bioidentical hormones over conventional menopausal hormone therapy, but these claims also pose the additional risks of variable purity and potency and lack efficacy and safety data"
• Under and overdosage are of concern, eg. endometrial hyperplasia and cancer are a concern with untested/unreliable doses of estrogen and progestins 
Menopause: Hot Flushes and Associated Symptoms

An Intensive Behavioral Weight Loss Intervention and Hot
Flushes in Women 338 overweight or obese women enrolled in a 6 month randomized controlled trail of an intensive behavioral weight loss intervention compared to a structured educational program to promote weight loss to improve urinary incontinence completed a self-administered questionnaire assessing hot flushes.
• 154 women endorsed that they were bothered by hot flushes at the start of the study. • Alternative and complementary therapies are similar to placebo in reducing hot flushes. This is a 25% to 50% reduction in symptoms in most studies.
• Weight loss improves hot flushes
Treatment of vaginal atrophy
• Topical treatments are efficacious and preferred as first line therapy
• Local estrogen treatments can be used without systemic progestins • Systemic treatments include hormone therapy (when also used for vasomotor symptoms) and ospemifene (an estrogen agonist/antagonist). Ospemifene increases hot flushes, and concerns remain about endometrial hyperplasia with longer term (greater than 15 month) use, as this has not been studied.
